Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427409 | 0.89 | IDO1 (0.35) | TSHRIDO1ERN1DAO | |
| SCHEMBL1160984 | 0.84 | DAO (0.39) | IDO1ERN1DAO | |
| SCHEMBL29953168 | 0.84 | DAO (0.39) | IDO1ERN1DAO | |
| SCHEMBL6368476 | 0.79 | MARS1 (0.42) | ERN1TP53AHRCNR1 | |
| SCHEMBL29813213 | 0.79 | ADRA1D (0.45) | — | |
| SCHEMBL23568677 | 0.78 | — | — | |
| SCHEMBL7335595 | 0.77 | DAO (0.40) | TSHRIDO1ERN1DAOTP53 | |
| SCHEMBL19043341 | 0.77 | CHKA (0.50) | TSHRAHRCNR1 | |
| SCHEMBL4083756 | 0.76 | TSHR (0.42) | TSHRIDO1TP53CYP3A4L3MBTL1 | |
| SCHEMBL8756021 | 0.76 | ALDH1A1 (0.41) | TSHRIDO1CYP3A4AHRHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | claimed |
| EP-1885720-A2 | 4-(THIAZOL-2-YLTHIOALKYL)-PYRAZOLES AND THEIR USE AS HERBICIDES | Syngenta Limited (GB) | 2008-02-13 | — | — | EP | claimed |
| WO-2006123088-A2 | 4- (THIAZOL-2-YLTHIOALKYL) -PYRAZOLES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2006-11-23 | — | — | WO | claimed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119775103-B | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119775103-A | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-09-26 | — | — | US | disclosed |
| WO-2024137968-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-1773330-A4 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| EP-1885720-A2 | 4-(THIAZOL-2-YLTHIOALKYL)-PYRAZOLES AND THEIR USE AS HERBICIDES | Syngenta Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| EP-1773330-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006123088-A2 | 4- (THIAZOL-2-YLTHIOALKYL) -PYRAZOLES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006014618-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-5945382-A | AND A METHOD OF THEIR PREPARATION BY CHLORINATION OF AN INTERMEDIATE ARYLPYRAZOLE; PROTECTION AGAINST FUNGAL DISEASES IN TOMATO, RICE, AND WHEAT PLANTS | RHONE-POULENC AGROCHIMIE (FR) | 1999-08-31 | — | — | US | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | TSHR 1084/4885IDO1 3095/4885ERN1 777/4885 |
| US-20090048112-A1 | Novel Herbicides | HAX1, MTX1, CYP4X1 | TSHR 417/4885IDO1 199/4885ERN1 1796/4885 |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, SAAL1, APOB | TSHR 2856/4885IDO1 2669/4885ERN1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.